#1 Clinical Trials Search in Europe

Captopril

Captopril, an angiotensin-converting enzyme (ACE) inhibitor, has been the subject of numerous clinical trials investigating its effectiveness in treating various medical conditions. These trials aim to evaluate captopril’s safety, efficacy, and potential benefits in different patient populations, ranging from cardiovascular disorders to rare genetic conditions. This article summarizes key findings from recent clinical trials involving captopril, providing insights into its diverse applications in modern medicine.

Table of Contents

What is Captopril?

Captopril is a medication that belongs to a class of drugs called Angiotensin-Converting Enzyme (ACE) inhibitors. It’s also known by its brand name Capoten[1]. Captopril is primarily used to treat various cardiovascular conditions and has been the subject of numerous clinical trials to explore its potential benefits in different medical scenarios.

Uses of Captopril

Captopril is used to treat several conditions, including:

  • High Blood Pressure (Hypertension): It’s commonly used to lower blood pressure in patients with hypertension, including those who have recently given birth[2].
  • Heart Failure: Captopril can help improve heart function in patients with heart failure[3].
  • Diabetic Nephropathy: This is a kidney condition that can occur in people with diabetes. Captopril has shown potential in reducing protein in the urine (proteinuria) in patients with this condition[4].
  • Bone Marrow Fibrosis: Research is being conducted to see if Captopril can help reduce scarring in the bone marrow in certain blood disorders[5].

How Captopril Works

Captopril works by inhibiting an enzyme in the body called angiotensin-converting enzyme (ACE). This enzyme is responsible for producing a substance called angiotensin II, which causes blood vessels to narrow. By blocking this enzyme, Captopril helps blood vessels relax and widen, which lowers blood pressure and improves blood flow[6].

Administration and Dosage

Captopril is typically taken orally in tablet form. The dosage can vary depending on the condition being treated and the individual patient. Here are some general guidelines:

  • For high blood pressure, a common starting dose is 25 mg three times a day[4].
  • In some cases, doctors may start with a lower dose of 12.5 mg and gradually increase it[6].
  • For heart conditions, doses may be adjusted based on the patient’s response and can range from 6.25 mg to 50 mg three times daily[3].

It’s crucial to follow your doctor’s instructions precisely when taking Captopril. Never adjust your dose without consulting your healthcare provider.

Potential Side Effects

Like all medications, Captopril can cause side effects. Some common ones include:

  • Dry cough
  • Dizziness
  • Headache
  • Nausea
  • Changes in taste

In rare cases, more serious side effects can occur. If you experience severe dizziness, fainting, or signs of an allergic reaction, seek medical attention immediately[1].

Ongoing Research

Researchers are continually studying Captopril to understand its potential benefits in various conditions:

  • Lung Cancer: Studies are investigating whether Captopril can help reduce side effects from radiation therapy in lung cancer patients[7].
  • Eye Health: Research is being conducted to see if Captopril affects blood flow in the eyes, particularly in patients with diabetes[8].
  • Heart Function in Duchenne Muscular Dystrophy: A study is looking at how Captopril might improve heart function in patients with this genetic disorder[9].

These ongoing studies highlight the potential of Captopril beyond its current uses, but more research is needed before any new applications can be confirmed.

Aspect Details
Primary Uses Hypertension, heart failure, diabetic nephropathy
Mechanism of Action ACE inhibitor, blocks production of angiotensin II
Conditions Studied Bone marrow fibrosis, lung cancer complications, postpartum hypertension, Duchenne muscular dystrophy
Dosage Forms Oral tablets, various strengths (e.g., 12.5mg, 25mg, 50mg)
Common Side Effects Dry cough, nausea, hypotension
Trial Durations Vary from weeks to over a year
Comparison Studies Versus clonidine for postpartum hypertension, combined with pentoxifylline for diabetic nephropathy
Special Populations Pregnant women, cancer patients, children with genetic disorders

FAQ

  • What is captopril and how does it work? Captopril is an angiotensin-converting enzyme (ACE) inhibitor. It works by blocking the production of angiotensin II, a substance that narrows blood vessels. This helps relax and widen blood vessels, making it easier for the heart to pump blood and reducing blood pressure.
  • In which medical conditions is captopril being studied? Captopril is being studied in various conditions, including hypertension, heart failure, diabetic nephropathy, bone marrow fibrosis, myeloproliferative neoplasms, lung cancer-related complications, postpartum high blood pressure, and Duchenne muscular dystrophy-related heart issues.
  • How is captopril being compared to other medications in clinical trials? In some trials, captopril is being compared to other medications. For example, one study compares captopril to clonidine for treating postpartum very high blood pressure. Another trial compares captopril alone to a combination of captopril and pentoxifylline for reducing proteinuria in diabetic nephropathy.
  • What are some potential side effects of captopril? Some reported side effects of captopril include dry cough, nausea, and hypotension (low blood pressure). However, the specific side effects can vary depending on the condition being treated and the individual patient.
  • How long do captopril clinical trials typically last? The duration of captopril clinical trials varies widely depending on the condition being studied and the specific research objectives. Some trials last for a few weeks or months, while others may follow patients for a year or more to assess long-term effects and safety.

Ongoing Clinical Trials on Captopril

  • Study of stopping heart failure medications in patients with non-ischemic cardiomyopathy who responded very well to cardiac resynchronization therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • A Study Testing Drug Combination for Heart Failure in Women Comparing Increased Doses to Standard Care

    Recruiting

    1 1 1 1
    Investigated drugs:
    Italy

  • Study on Preventing Heart Disease in Diabetes Patients Using Eprosartan Mesilate and Drug Combination

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Austria Spain

  • Study of XXB750 and Drug Combination for Patients with Heart Failure

    Not recruiting

    1 1
    Investigated drugs:
    Bulgaria Czechia Denmark France Germany Hungary +5

Glossary

  • Angiotensin-Converting Enzyme (ACE) Inhibitor: A type of medication that helps relax blood vessels by blocking the production of angiotensin II, a substance that narrows blood vessels.
  • Bioequivalence: The property of two drug products having the same biological effect in the body, typically referring to the comparison between a generic drug and its brand-name counterpart.
  • Diabetic Nephropathy: Kidney damage that occurs as a complication of diabetes, often leading to kidney failure if left untreated.
  • Myeloproliferative Neoplasm: A group of slow-growing blood cancers where the bone marrow makes too many red blood cells, white blood cells, or platelets.
  • Global Longitudinal Strain: A measure of the heart's ability to contract, used to assess heart function in conditions like Duchenne muscular dystrophy.
  • Proteinuria: The presence of excess proteins in the urine, often a sign of kidney damage or disease.
  • Cardiotoxicity: Damage to the heart muscle or a change in the heart's electrical activity, often caused by cancer treatments like chemotherapy or radiation.
  • Up-titration: The process of gradually increasing the dose of a medication to achieve the desired therapeutic effect while minimizing side effects.

References

  1. https://clinicaltrials.gov/study/NCT04878315
  2. https://clinicaltrials.gov/study/NCT01761916
  3. https://clinicaltrials.gov/study/NCT00742040
  4. https://clinicaltrials.gov/study/NCT00663949
  5. https://clinicaltrials.gov/study/NCT04629651
  6. https://clinicaltrials.gov/study/NCT03389724
  7. https://clinicaltrials.gov/study/NCT00077064
  8. https://clinicaltrials.gov/study/NCT01626469
  9. https://clinicaltrials.gov/study/NCT06485661